---
id: ash-aml-older-adults-2025
title: "ASH 2025 Clinical Practice Guideline for the Treatment of Acute Myeloid Leukemia in Older Adults"
short_title: "ASH AML Older Adults 2025"

organization: American Society of Hematology
collaborators: null
country: US
url: https://ashpublications.org/blood/article/doi/10.1182/blood.2024000000
doi: 10.1182/blood.2024000000
pmid: null
open_access: true

specialty: hematology
guideline_type: clinical-practice
evidence_system: GRADE
conditions:
  - acute myeloid leukemia
  - AML
  - leukemia
tags:
  - geriatric oncology
  - venetoclax
  - hypomethylating agents
  - palliative care
  - goal-concordant care

publication_date: 2025-11-15
previous_version_date: null
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-23
---

## Scope
New comprehensive evidence-based recommendations for clinicians treating older adults (typically â‰¥65 years) with AML, addressing the assessment of fitness, selection of therapy, and integration of supportive and palliative care.

## Key Recommendations

### Assessment of Fitness
- **Comprehensive Geriatric Assessment (CGA)**: Recommended for all older adults with AML to assess functional status, comorbidities, and cognitive function.
- **Fitness Classification**: Use objective tools to categorize patients as "fit for intensive therapy," "fit for non-intensive therapy," or "unfit for leukemia-directed therapy."

### Treatment Selection (Non-intensive)
- **HMA + Venetoclax**: Recommended as the standard of care for older adults who are not candidates for intensive chemotherapy (e.g., 7+3).
- **Maintenance**: In patients achieving remission with non-intensive therapy, continued treatment is recommended to delay relapse.

### Treatment Selection (Intensive)
- **Selection**: Intensive induction should only be offered to older adults with favorable or intermediate-risk cytogenetics who have high functional status (ECOG 0-1) and minimal comorbidities.

### Goal-Concordant Care
- **Discussion**: Clinicians must engage in early and ongoing discussions about patient values, treatment goals (e.g., survival vs. quality of life), and the expected outcomes of different therapeutic paths.
- **Palliative Care**: Early integration of palliative care is recommended regardless of the plan for leukemia-directed therapy.

### Supportive Care
- **Transfusion Support**: Proactive and individualized transfusion strategy.
- **Infection Prophylaxis**: Use of antifungal, antiviral, and antibacterial prophylaxis based on the specific treatment regimen and local resistance patterns.
